Cover Image
市場調查報告書

原發性高草酸鹽尿症治療藥:開發中產品分析

Primary Hyperoxaluria - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 474978
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
原發性高草酸鹽尿症治療藥:開發中產品分析 Primary Hyperoxaluria - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 44 Pages
簡介

本報告提供原發性高草酸鹽尿症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,暫停中·中止的計劃等相關資訊。

簡介

  • 調查範圍

原發性高草酸鹽尿症 - 概要

原發性高草酸鹽尿症 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 企業開發中的產品

原發性高草酸鹽尿症 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

原發性高草酸鹽尿症的開發治療藥的企業

原發性高草酸鹽尿症 - 藥物簡介

原發性高草酸鹽尿症 - 暫停中的計劃

原發性高草酸鹽尿症 - 開發中止的產品

原發性高草酸鹽尿症 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10196IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline Review, H1 2018, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called oxalate. Symptoms include blood in the urine, pain when urinating, fever, sudden abdominal pain and frequent urge to urinate. Treatment includes Oral preparations of phosphates and diuretics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Hyperoxaluria - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 1, 1, 2 and 1 respectively.

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Hyperoxaluria - Overview
    • Primary Hyperoxaluria - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Primary Hyperoxaluria - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Hyperoxaluria - Companies Involved in Therapeutics Development
    • Allena Pharmaceuticals Inc
    • Alnylam Pharmaceuticals Inc
    • Dicerna Pharmaceuticals Inc
    • Intellia Therapeutics Inc
    • OxThera AB
  • Primary Hyperoxaluria - Drug Profiles
    • ALLN-177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-GO1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCR-PHXC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides for Primary Hyperoxaluria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oxabact - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Hyperoxaluria - Dormant Projects
  • Primary Hyperoxaluria - Discontinued Products
  • Primary Hyperoxaluria - Product Development Milestones
    • Featured News & Press Releases
      • Dec 07, 2017: Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria
      • Nov 03, 2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1
      • Oct 16, 2017: Dicerna Files Clinical Trial Application for DCR-PHXC, the Company's Most Advanced GalXC Product Candidate, for Phase 1 Study in Primary Hyperoxaluria
      • Jul 27, 2017: European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals Investigational Therapy for the Treatment of Primary Hyperoxaluria
      • Jul 17, 2017: Dicerna Expands Lead GalXC Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC
      • Jul 13, 2017: FDA Grants Orphan Drug Designation to Allena Pharmaceuticals' Investigational Therapy for the Treatment of Primary Hyperoxaluria
      • Jul 05, 2017: Matthew Gantz Appointed CEO of OxThera
      • Sep 24, 2016: Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
      • Mar 09, 2016: Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
      • Dec 21, 2015: Alnylam Files Clinical Trial Application for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
      • Sep 08, 2015: Alnylam Accelerates Development of ALN-GO1, a Subcutaneously Administered Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
      • Oct 14, 2014: Alnylam Pharmaceuticals Presents Pre-Clinical Data From New Program, ALN-GO1, At 10th Oligonucleotide Therapeutics Society Meeting
      • Jan 08, 2014: OxThera Initiates Clinical Trial in Primary Hyperoxaluria
      • Jun 04, 2013: OxThera Strengthens Patent Portfolio For Orphan Disease
      • Apr 03, 2008: Pivotal study is being conducted with Oxabact for the treatment of Primary Hyperoxaluria
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Primary Hyperoxaluria, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Primary Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H1 2018
  • Primary Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
  • Primary Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
  • Primary Hyperoxaluria - Pipeline by Intellia Therapeutics Inc, H1 2018
  • Primary Hyperoxaluria - Pipeline by OxThera AB, H1 2018
  • Primary Hyperoxaluria - Dormant Projects, H1 2018
  • Primary Hyperoxaluria - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Primary Hyperoxaluria, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top